Rachel Burga is a Principal Scientist at Obsidian Therapeutics, where Rachel pioneers controllable cell and gene therapies. Rachel has a background in immunology, with experience as a Postdoctoral Scholar at Northwestern University and The George Washington University. Additionally, Rachel has research experience in tissue engineering therapies and has worked on projects focusing on liver immunotherapy and osteoarthritis. Rachel has also interned at IRphotonics and conducted research at Columbia University during their undergraduate studies.
Links
Previous companies
Org chart
Sign up to view 0 direct reports
Get started